Ionis partners up with Metagenomi on drug discovery pact, shelling out $80M upfront
Ionis is no stranger to large deals and working with other entities, but its latest deal will see the company work Metagenomi to go after the liver.
The pair will conduct research to deliver up to four genetic targets, with Ionis having the right to add four additional targets once certain milestones have been hit. The terms of the agreement have Ionis paying $80 million upfront to Metagenomi, plus the potential for future milestone payments, which remain undisclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.